Home » Eli Lilly Plans a Response on Bydureon This Week, Estimates Health Reform Costs
Eli Lilly Plans a Response on Bydureon This Week, Estimates Health Reform Costs
Eli Lilly and its partners
plan to submit a response this week to the FDA’s complete response letter on once-weekly diabetes drug Bydureon. Last
month, Lilly, Alkermes and Amylin Pharmaceuticals received a complete response letter requesting final labeling information and a risk evaluation and mitigation
strategy for Bydureon (exenatide). The drug also is under review by the European Medicines Agency, the company said.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May